Publication Cover

American Journal of Respiratory Cell and Molecular Biology

Publishes the most significant and original observations in the area of respiratory and lung cell biology, including cellular, biochemical, molecular, developmental, genetic, and immunologic studies in health and in acute and chronic disorders related to the respiratory system and sleep

Red in Motion

News & Announcements

Call for Applications for the Editor Apprentice Program.
ATS Journals has waived submission fees.
This call focuses on the use and impact of multiple omics technologies associated with respiratory diseases, lung development, and precision medicine strategies.
The 2023 impact factors are now available.
We are thrilled to announce the winners of the 2023 AJRCMB Junior Investigator Awards.
In recognition of their exemplary work, the AJRCMB editors are delighted to present the 2023 Journal Reviewer Award winners.
This page will serve as a hub for all COVID-19 related manuscripts published across all four ATS Journals.

Current Issue Highlights

The authors present a novel finding that the interstitial macrophage, not the alveolar macrophage, primarily mediates clearance of AT2 cells in the lungs after influenza infection. Their method of studying efferocytosis provides a more physiologic approach in evaluating the spatiotemporal dynamics of apoptotic cell clearance in vivo and opens new avenues to study the mechanisms by which efferocytosis regulates inflammation.
There is evidence of increased methylation of CDH1 (the gene for E-cadherin) in moderate-severe chronic obstructive pulmonary disease (COPD). The authors provide molecular evidence that targeted changes in the enhancer element decreases protein production, and targeting this improved lung epithelial function and tissue function. These findings suggest that reversing CDH1 DNA methylation could be a potential therapeutic strategy for COPD.
A novel biomarker, GOLM1 (Golgi membrane protein 1), has been found to be critical in pulmonary fibrosis. GOLM1 promotes pulmonary fibrosis through the KLF4/NEAT1 signaling pathway. Targeting GOLM1 may be a promising strategy for treating pulmonary fibrosis.
A lack of S1PR2 modulates the type 2 immune response by upregulating IL-33 release from macrophages and alleviates sepsis-induced lung injury. Targeting S1PR2 may have potential therapeutic value for sepsis treatment.

Journal Metrics

Impact Factor
Google h5-index 45
Full-Text Views
~1.6 Million
More Metrics